Haemoglobin at time of referral prior to dialysis predicts survival:an association of haemoglobin wi

来源 :2013年中国肾性贫血治疗专家共识研讨会 | 被引量 : 0次 | 上传用户:wormchen
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Haemoglobin (Hgb) levels are known to be associated with numerous adverse outcomes in both chronic kidney disease (CKD) and non-CKD patients.This analysis evaluates the association of baseline haemoglobin levels on survival in CKD patients, who are followed by nephrologists, irrespective of glomerular filtration rate (GFR), prior to initiation of renal replacement therapy (RRT) and erythropoietin hormone replacement therapy.Analysis of data from the provincial database (PROMIS, Patient Registration and Outcome Management Information System) in British Columbia, Canada, was undertaken.Records used for the analysis included all CKD patients at first registration: GFR <60ml/min/1.73 m2, not yet on dialysis, starting from May 1998 to October 2002, and who had complete data (defined as age and gender, diabetic status, eGFR and Hgb levels).The primary objective of this study was to determine the association of Hgb and survival controlling for eGFR at first registration value, age, gender and diabetic status.Multivariate Cox proportional hazards analysis with time to death as outcome variable was performed.The cohort included 3028 patients: the mean age was 65 years, 28% were diabetic, and the mean eGFR in the cohort was 21ml/min/1.73m2.The cohort is representative of the BC CKD and dialysis population regarding ethnicity: 64% Caucasian, 32% Asian.Median follow-up was 27 months, 1 year survival was 0.92, 2 year survival was 0.85.Hgb at initial registration is a statistically independent predictor of survival (RR=0.875 for every 10g/l, 95% CI: 0.835-0.917,P=0.0001), after adjusting for age, gender, diabetic status and baseline eGFR.Further analysis,controlling for RRT, demonstrated a similar association between Hgb and survival (RR =0.853 for every 10g/l, 95% CI: 0.799-0.910, P=0.0001), after adjusting for above variables.Substantial variation in Hgb values exists at all GFR levels.These findings underscore the importance of evaluating Hgb at all GFR levels, and the need to study the impact of modification of Hgb at different GFR levels on survival.
其他文献
目的:探讨外周血microRNA 101 (miR-101)表达水平在成人急性髓性白血病(Acute Myeloid Leukemia, AML)患者预后评估中的价值.方法:采用Real-time PCR法,检测初诊AML(非M3)患者及正常人外周血白细胞的microRNA 101水平,收集患者的临床特征和预后资料,统计分析它们之间的相关性.结果:初诊AML患者外周血的miR-101表达水平存在较
目的:研究分析髓系抗原(MyAg)表达在急性淋巴细胞白血病(Acute Lymphoblastic Leukemia, ALL)中的表达情况及其与预后的相关性.方法:选择中山大学附属中山医院2001年1月~2010年12月收治的初诊的成人急性淋巴细胞白血病病例共137例,所有患者均进行了骨髓细胞形态学、白血病免疫分型检查及Ph染色体检查,部分患者进行了分子生物学检测,分析髓系抗原在ALL中的表达情
目的:研究不同方案作为伴t(8; 21)急性髓系白血病缓解后的巩固治疗对疾病预后的影响。方法:回顾性分析多中心诊断的诱导缓解后接受≥2疗程巩固治疗的111例伴t(8; 21) AML患者的临床资料,分析不同巩固方案对OS和PFS的影响。结果:(1) 111例患者[男:女=65:46,中位年龄25(2-60)岁]中接受常规方案巩固化疗者(A组)有36例,含DAE、<4程MiDAC、<3程HiDAC强
目的:探讨利妥昔单抗对弥漫大B细胞淋巴瘤患者Th17细胞及相关细胞因子体外的影响及其意义。方法:DLBCL初治患者和体检健康者各20例,每个对象分别采集4份外周血标本,分离外周血单个核细胞(PBMCs),按照培养条件的不同分成4个亚组:空白组(A亚组)、加入利妥昔单抗组(B亚组)、加入利妥昔单抗和血清组(C亚组)和极化组(D亚组)(加IL-6和TGF-β)。
背景和目的:多发性骨髓瘤患者RANKL表达异常增高使RANKL/RANK信号系统过度激活,导致破骨细胞(Osteoclast,oC)大量生成且功能亢进在骨髓瘤骨病(Myeloma bone disease,MBD)的发生、发展中起关键作用,因此抑制RANKL/RANK信号转导途径从而抑制OC的形成及其破骨功能是治疗MBD有效方法之一。前期研究发现RANK蛋白上存在一个新基序:IVVY,介导了一条O
会议
背景反复输血或使用红细胞生成刺激剂(ESA)都可以用于治疗肾性贫血.但是对两种治疗方法的选择,应该针对患者的实际情况,根据两种治疗方法的相对利弊进行选择.单纯的Hb降低不作为输血的理由,不能为了Hb达标而输血.慢性贫血患者输血是为了防止组织缺氧或心力衰竭.在ESA治疗Hb达标的患者,仅在急性失血(如急性出血、急性溶血、严重炎症或外科血液丢失)时输血.输血患者患急性冠脉综合征时有更高的死亡率.使用输
会议
Background.Recent clinical trials in cancer patients treated with erythropoiesis-stimulating agents (ESAs) and in CKD patients treated to haemoglobin (Hb) targets above the labeled range of 10-12 g/dL
Background and Objectives: Instability of hemoglobin levels during epoetin therapy is a new problem in hemodialysis.We evaluated extent and correlates of time in target, that is, the time spent with h
会议
Background: Anaemia is a known risk factor for cardiovascular disease and treating anaemia in chronic kidney disease (CKD) may improve outcomes.However, little is known about the scope to improve prim
Objective-To determine whether recombinant human erythropoietin improves the quality of fife and exercise capacity of anaemic patients receiving haemodialysis.Design-A double blind, randomised, placeb
会议